What is Biolocity?
A philanthropic, multi-institutional program supporting and accelerating the commercialization of early-stage medical technologies with intellectual property held at Emory University and/or Georgia Institute of Technology.
The Biolocity approach encompasses three components:
Biolocity U – educational resources focused on life-science commercialization, including consultations, workshops, internships, and legal office hours.
Biolocity Fund – more than $1.5 million in funding available each year to Emory and Georgia Tech innovations through a multi-stage, competitive application process.
Biolocity Launch – active project management and formal coordination with the life-sciences commercialization ecosystem for Biolocity Fund awardees.
Biolocity by the numbers…
Lab2Launch is a coworking environment designed to support scientist-entrepreneurs in taking their discoveries from the lab to market and fostering collaboration between scientists. The lab will be housed on the 1st Floor of the Health Sciences Research Building (HSRB) II on the Emory University campus and is slated to open in Spring 2023.
To learn more and download the brochure, visit here.
Currently funded projects:
- Athena: An early-stage cell therapy company developing a mesothelin-specific chimeric antigen receptor (CAR) T cell product, for the treatment of mesothelioma and other mesothelin expressing solid tumors. Principal Investigator: Crystal Paulos, Ph.D. (Emory University).
- Bystro by revXon: A search engine for your life-sciences data. Principal Investigator: Thomas Wingo, MD (Emory University).
- DexaPatch: Low-swelling, steroid-releasing, implantable hydrogel platform to reduce post-operative inflammation in tight surgical spaces. Principal Investigators: Andrés Garcia, Ph.D. (Georgia Tech), Adam Klein, M.D., Daniel Refai, M.D., Stephen Linderman, M.D., Ph.D. (Emory).
- MagTrack: MagTrack is a wearable alternative controller that simplifies power wheelchair driving and the control of digital devices for people living with tetraplegia. Principal Investigators: Nordine Sebhki, Ph.D., and. Omer Inan, Ph.D. (Georgia Tech).
- Orally Bioavailable CXCR4 Antagonists for the Treatment of Cancer: Best-In-Class Orally Bioavailable CXCR4 Antagonists Heat Up Solid Tumors. Principal Investigators: Dennis Liotta, Ph.D., Eric Miller, Ph.D., Haydn Kissick, Ph.D., and John Petros, M.D. (Emory University).
- ProLymph Nano: Drug delivery technology unlocks new market opportunities by targeting the lymphatic system. Principal Investigator: Susan Thomas, Ph.D. (Georgia Tech).